Absher Wealth Management LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 215,584 shares of the company's stock after purchasing an additional 2,469 shares during the period. Johnson & Johnson makes up approximately 4.7% of Absher Wealth Management LLC's holdings, making the stock its 2nd largest position. Absher Wealth Management LLC's holdings in Johnson & Johnson were worth $35,752,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Inlight Wealth Management LLC acquired a new position in Johnson & Johnson in the 1st quarter valued at approximately $121,000. Intact Investment Management Inc. raised its holdings in Johnson & Johnson by 3.2% in the 1st quarter. Intact Investment Management Inc. now owns 87,289 shares of the company's stock valued at $14,476,000 after acquiring an additional 2,700 shares in the last quarter. Burt Wealth Advisors raised its holdings in Johnson & Johnson by 3.1% in the 1st quarter. Burt Wealth Advisors now owns 12,778 shares of the company's stock valued at $2,119,000 after acquiring an additional 381 shares in the last quarter. Center For Asset Management LLC acquired a new position in Johnson & Johnson in the 1st quarter valued at approximately $205,000. Finally, Bernardo Wealth Planning LLC raised its holdings in Johnson & Johnson by 2.4% in the 1st quarter. Bernardo Wealth Planning LLC now owns 6,493 shares of the company's stock valued at $1,077,000 after acquiring an additional 155 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.
Analyst Upgrades and Downgrades
JNJ has been the subject of several recent research reports. Bank of America cut their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday, June 5th. Finally, Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $170.88.
View Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Stock Down 0.6%
NYSE JNJ opened at $149.81 on Monday. The firm has a market cap of $360.44 billion, a PE ratio of 16.66, a price-to-earnings-growth ratio of 2.27 and a beta of 0.42. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The stock's 50 day simple moving average is $154.07 and its 200 day simple moving average is $153.68. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.47%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
